Published in Psychiatr Serv on May 01, 2008
GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia. Neural Plast (2011) 1.51
Racial and ethnic disparities in the treatment of a Medicaid population with schizophrenia. Health Serv Res (2009) 0.94
Improving quality and diffusing best practices: the case of schizophrenia. Health Aff (Millwood) (2009) 0.91
How quickly do physicians adopt new drugs? The case of second-generation antipsychotics. Psychiatr Serv (2013) 0.90
Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory. Pharmacoepidemiol Drug Saf (2012) 0.89
Evaluation of the clinical efficacy of asenapine in schizophrenia. Expert Opin Pharmacother (2010) 0.86
Changes in physician antipsychotic prescribing preferences, 2002-2007. Psychiatr Serv (2014) 0.84
The role of α5 GABAA receptor agonists in the treatment of cognitive deficits in schizophrenia. Curr Pharm Des (2014) 0.81
The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity. Eur J Clin Nutr (2013) 0.80
The effect of race-ethnicity and geography on adoption of innovations in the treatment of schizophrenia. Psychiatr Serv (2012) 0.79
Neuropsychiatric disorders: The choice of antipsychotics in schizophrenia. Nat Rev Neurol (2009) 0.78
How have developments in molecular imaging techniques furthered schizophrenia research? Imaging Med (2009) 0.77
Beyond informed consent: the ethics of informing, anticipating, and warning. Psychiatry (Edgmont) (2008) 0.75
Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical Record. Prim Care Companion CNS Disord (2016) 0.75
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull (2004) 7.58
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry (2008) 3.13
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull (2009) 2.61
Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia. Arch Gen Psychiatry (2006) 1.86
Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry (2008) 1.81
Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry (2008) 1.78
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry (2007) 1.73
Voxel-based morphometry versus region of interest: a comparison of two methods for analyzing gray matter differences in schizophrenia. Schizophr Res (2005) 1.69
Evoked gamma band synchronization and the liability for schizophrenia. Schizophr Res (2004) 1.65
Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. Am J Psychiatry (2002) 1.62
Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull (2008) 1.52
Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology (2009) 1.41
Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull (2006) 1.39
Galantamine-induced QTc prolongation. J Clin Psychiatry (2006) 1.38
Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.37
Visual perceptual and working memory impairments in schizophrenia. Arch Gen Psychiatry (2002) 1.36
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry (2004) 1.35
Significance and meaning of neurological signs in schizophrenia: two decades later. Schizophr Bull (2005) 1.34
Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry (2011) 1.33
Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status. Schizophr Res (2004) 1.33
Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull (2006) 1.30
No, it is not possible to be schizophrenic yet neuropsychologically normal. Neuropsychology (2005) 1.29
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology (2009) 1.28
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology (2007) 1.27
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biol Psychiatry (2011) 1.26
Factor structure of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.23
Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2003) 1.18
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res (2011) 1.17
Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res (2013) 1.16
An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry (2002) 1.16
Prefrontal cortex and insight in schizophrenia: a volumetric MRI study. Schizophr Res (2006) 1.12
Working memory for visual features and conjunctions in schizophrenia. J Abnorm Psychol (2003) 1.11
Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. Arch Gen Psychiatry (2004) 1.09
Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study. Schizophr Res (2013) 1.08
Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res (2011) 1.08
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2011) 1.08
The Wisconsin Card Sorting impairment in schizophrenia is evident in the first four trials. Schizophr Res (2007) 1.07
A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol (2012) 1.04
Gamma/beta oscillation and sensory gating deficit in schizophrenia. Neuroreport (2004) 1.04
Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull (2003) 1.04
Independent domains of inhibitory gating in schizophrenia and the effect of stimulus interval. Am J Psychiatry (2007) 1.02
White matter alterations in deficit schizophrenia. Neuropsychopharmacology (2008) 1.02
Beta (~16 Hz) frequency neural oscillations mediate auditory sensory gating in humans. Psychophysiology (2007) 0.99
The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry (2004) 0.98
Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull (2011) 0.97
The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Am J Psychiatry (2003) 0.96
The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull (2002) 0.92
A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry (2009) 0.92
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology (2013) 0.92
Differential patterns of premorbid social and academic deterioration in deficit and nondeficit schizophrenia. Schizophr Res (2011) 0.91
Association between polymorphism of the SNAP29 gene promoter region and schizophrenia. Schizophr Res (2005) 0.89
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res (2011) 0.89
Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. J Clin Psychiatry (2011) 0.88
Smoking history and motivation to quit in smokers with schizophrenia in a smoking cessation program. Schizophr Res (2010) 0.87
Advancing drug discovery for schizophrenia. Ann N Y Acad Sci (2011) 0.86
Cortical structural abnormalities in deficit versus nondeficit schizophrenia. Schizophr Res (2012) 0.86
Evidence-based early interventions for individuals at clinical high risk for psychosis: a review of treatment components. J Nerv Ment Dis (2015) 0.85
Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res (2003) 0.85
Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia. Schizophr Res (2008) 0.85
Evidence-based treatment for schizophrenia. Psychiatr Clin North Am (2003) 0.85
Antipsychotic dosing and concurrent psychotropic treatments for Medicaid-insured individuals with schizophrenia. Schizophr Bull (2002) 0.85
Differences in developmental changes in academic and social premorbid adjustment between males and females with schizophrenia. Schizophr Res (2013) 0.84
Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia. Psychiatry Res (2008) 0.84
Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. J Clin Psychiatry (2013) 0.83
Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2005) 0.83
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology (2010) 0.83
Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res (2011) 0.83
Olanzapine effects on auditory sensory gating in schizophrenia. Am J Psychiatry (2003) 0.82
Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology (Berl) (2014) 0.81
Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses (2011) 0.81
The effects of galantamine on psychopathology in chronic stable schizophrenia. Clin Neuropharmacol (2009) 0.81
Important steps in the development of cognitive-enhancing drugs in schizophrenia. Am J Psychiatry (2006) 0.80
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. J Clin Psychopharmacol (2015) 0.80
Lack of association between COMT gene and deficit/nondeficit schizophrenia. Behav Brain Funct (2006) 0.79
The family pictures test as a measure of impaired feature binding in schizophrenia. J Clin Exp Neuropsychol (2004) 0.79
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC Psychiatry (2013) 0.78
Commentary on the Soteria project: misguided therapeutics. Schizophr Bull (2002) 0.78
The potential of nicotinic enhancement of cognitive remediation training in schizophrenia. Neuropharmacology (2012) 0.78
Community adherence to schizophrenia treatment and safety monitoring guidelines. J Nerv Ment Dis (2014) 0.76
Use of clozapine in older Asian patients with schizophrenia between 2001 and 2009. PLoS One (2013) 0.75
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2013) 0.75
Research and services partnerships: the practice research network: a successful collaboration in Maryland. Psychiatr Serv (2013) 0.75
Weight and blood pressure change during clozapine treatment. Clin Neuropharmacol (2002) 0.75
Celebrating the work of William T. Carpenter Jr. Schizophr Bull (2014) 0.75
Open-label salsalate for the treatment of pre-diabetes in people with schizophrenia. Schizophr Res (2013) 0.75